Research Compound
TIRZ
Dual GIP / GLP-1 receptor agonist investigated in metabolic research.
For research use only. Not for human consumption.
From $79.00
99%+ by HPLCDual HPLC verification — synthesis partner + independent third-party laboratory
Ships from CanadaCanadian domestic tracked shipping
Sealed & LyophilizedGlass vial, tamper-evident, lot-traceable
For Research Use Only.
Not for human or veterinary consumption. By purchasing you affirm you are 19 or older and a qualified researcher operating under appropriate institutional protocols.
Compound Detail
About TIRZ
Tirzepatide is a first-in-class, 39-amino-acid synthetic linear peptide engineered for the study of dual metabolic pathways. Structurally based on the native gastric inhibitory polypeptide (GIP) sequence, it is modified with a C20 fatty diacid moiety to prolong its plasma half-life in comparative animal models. It serves as a crucial tool for investigating synergistic GIP and GLP-1 receptor co-agonism (“twincretin” signaling).
Key Areas of Scientific Interest
- Imbalanced Receptor Engagement: Laboratories utilize Tirzepatide to examine its biased signaling cascade. It possesses native-like affinity for the GIP receptor but exhibits roughly five-times weaker binding affinity for the GLP-1 receptor, minimizing early receptor desensitization.
- Glucose-Dependent Insulinotropic Profiles: In vitro and in vivo models investigate its dual ability to vigorously stimulate pancreatic beta-cell insulin secretion when glucose is elevated while simultaneously suppressing abnormal glucagon release from alpha cells.
- Adipocyte and Lipid Metabolism: Research focuses on how GIP receptor activation directly modifies adipose tissue function. It is studied for upregulating lipoprotein lipase (LPL) activity to enhance metabolic flexibility and fatty acid utilization.
- Hypothalamic Appetite Regulation: Investigators evaluate its dual-pathway penetration of the blood-brain barrier to assess central nervous system signaling. This includes tracking decelerated gastric emptying and central satiety markers.
- Cardiorenal and Pleiotropic Signaling: Recent trials explore downstream impacts on systemic inflammation biomarkers (such as C-reactive protein) and potential protective mechanisms within cardiorenal tissue models.
For research use only. Not for human consumption.
In-Vitro Research
Investigated in controlled in-vitro models within published research protocols.
Lot Traceability
Every vial carries a lot ID matched to a lot-specific Certificate of Analysis on file.
Dual HPLC Verification
Each released lot is reviewed through HPLC testing by our synthesis partner and an independent third-party laboratory before release.
